https://www.selleckchem.com/products/KU-60019.html
The treatment-related adverse events were observed in 82.0% (141 of 172) of patients, and 17.4% (30 of 172) had grade greater than or equal to 3, among which decreased neutrophil count (2.9%), leukopenia (2.9%), and pneumonia (2.9%) were the most common. The overall blinded independent central review-evaluated objective response rate was 59.3% (102 of 172, 95% confidence interval 51.6-66.7), and the median progression-free survival was 9.7 (95% confidence interval 8.3-11.1) months. Rezivertinib was found to have promising efficacy with
Respect!
Kommentar
Delen
